BiotechTube
Lumos Pharma

Lumos Pharma

LUMO
Austin, United States· Est.
lumos-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $110M

Overview

Lumos Pharma is a clinical-stage biotech dedicated to developing oral therapies for rare diseases, with a lead program targeting Pediatric Growth Hormone Deficiency (PGHD). Its strategy centers on identifying compounds for clear, high-need pathophysiology to enable time- and cost-efficient development. A key achievement was the successful merger with NewLink Genetics, which provided a public listing and resources, and recent Phase 2 trials for LUM-201 have met primary and secondary endpoints, positioning the company for a pivotal Phase 3 study.

EndocrinologyRare Diseases

Technology Platform

Focus on oral small molecule therapeutics targeting well-characterized pathways in rare diseases, with a lead platform based on an oral growth hormone secretagogue (GHS) mechanism designed to stimulate physiologic, pulsatile hormone release.

Funding History

3
Total raised:$110M
IPO$60M
Series B$35M
Series A$15M

Opportunities

LUM-201 addresses a multi-billion dollar pediatric growth hormone market dominated by daily injections, presenting a massive opportunity for a first-in-class oral therapy that could dramatically improve patient compliance and quality of life.
Orphan drug designation offers potential for premium pricing, exclusivity, and streamlined development.

Risk Factors

High clinical risk as the company approaches pivotal Phase 3 testing; failure would be catastrophic.
Significant future capital required to fund Phase 3 and commercialization, posing dilution risk.
As a small biotech, faces commercial execution risk against large, entrenched competitors with injectable products.

Competitive Landscape

Competes against established injectable recombinant growth hormone products from large pharma (Pfizer, Novo Nordisk, Eli Lilly). LUM-201's primary differentiation is its oral route of administration, facing no direct oral competitors currently, but longer-acting injectables and other secretagogues in development pose future threats.

More companies in Rare & Orphan Diseases →More companies in United States →